Company News-Bio-Thera Solutions, Ltd.

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

01-102020

Bio-Thera Solutions Launches First Commercial Product, QLETLI® (格乐立®), in China

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced...
12-042019

Bio-Thera Solutions Announces NMPA approval of IND Application to Initiate Phase I Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced t...
11-072019

China NMPA Approves Bio-Thera Solutions' QLETLI®, A Biosimilar To Humira® (Adalimumab)

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced t...

上一页 ···26 27 28 29 30 ··· 下一页